Geode Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-983,836
| Closed | -$1.56M | – | 4702 |
|
|
2024
Q1 | $1.56M | Buy |
983,836
+62,226
| +7% | +$99K | ﹤0.01% | 3207 |
|
|
2023
Q4 | $792K | Buy |
921,610
+34,709
| +4% | +$29.8K | ﹤0.01% | 3438 |
|
|
2023
Q3 | $949K | Buy |
886,901
+35,945
| +4% | +$38.5K | ﹤0.01% | 3348 |
|
|
2023
Q2 | $2.2M | Buy |
850,956
+60,119
| +8% | +$156K | ﹤0.01% | 3080 |
|
|
2023
Q1 | $3.23M | Buy |
790,837
+42,113
| +6% | +$172K | ﹤0.01% | 2824 |
|
|
2022
Q4 | $3.76M | Buy |
748,724
+11,408
| +2% | +$57.3K | ﹤0.01% | 2804 |
|
|
2022
Q3 | $9.64M | Buy |
737,316
+8,702
| +1% | +$114K | ﹤0.01% | 2289 |
|
|
2022
Q2 | $9.34M | Buy |
728,614
+26,300
| +4% | +$337K | ﹤0.01% | 2299 |
|
|
2022
Q1 | $10.7M | Buy |
702,314
+4,340
| +0.6% | +$66.2K | ﹤0.01% | 2304 |
|
|
2021
Q4 | $12.4M | Buy |
697,974
+54,101
| +8% | +$958K | ﹤0.01% | 2306 |
|
|
2021
Q3 | $13.5M | Buy |
643,873
+68,077
| +12% | +$1.43M | ﹤0.01% | 2243 |
|
|
2021
Q2 | $11.4M | Buy |
575,796
+117,483
| +26% | +$2.32M | ﹤0.01% | 2372 |
|
|
2021
Q1 | $13.3M | Buy |
458,313
+112,796
| +33% | +$3.28M | ﹤0.01% | 2151 |
|
|
2020
Q4 | $10.5M | Buy |
345,517
+44,258
| +15% | +$1.34M | ﹤0.01% | 2148 |
|
|
2020
Q3 | $4.79M | Buy |
301,259
+56,879
| +23% | +$905K | ﹤0.01% | 2423 |
|
|
2020
Q2 | $4.82M | Buy |
244,380
+9,592
| +4% | +$189K | ﹤0.01% | 2356 |
|
|
2020
Q1 | $2.89M | Buy |
234,788
+47,697
| +25% | +$588K | ﹤0.01% | 2463 |
|
|
2019
Q4 | $3.46M | Buy |
187,091
+92,660
| +98% | +$1.71M | ﹤0.01% | 2672 |
|
|
2019
Q3 | $1.31M | Sell |
94,431
-4,750
| -5% | -$65.7K | ﹤0.01% | 3137 |
|
|
2019
Q2 | $1.45M | Buy |
+99,181
| New | +$1.45M | ﹤0.01% | 3103 |
|